# Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

> **NCT07198074** · PHASE3 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 255 (estimated)

## Conditions studied

- Advanced Endometrial Carcinoma
- Recurrent Endometrial Carcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Carboplatin
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07198074
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-27
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07198074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07198074, "Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07198074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*